Table 2.
Cardiovascular outcome trials (CVOTs) of GLP-1RAs
| GLP-1RAs | Trails | Patients | Median duration of follow-up | Outcomes | References | ||
|---|---|---|---|---|---|---|---|
| MACE | CV Death | HHF | |||||
| Lixisenatide | ELIXA NCT01147250 |
6068 T2DM patients recently suffering acute coronary syndrome | 2.1 | 1.02 (0.89-1.17) | 0.98 (0.78-1.22) | 0.96 (0.75-1.23) | 47 |
| Liraglutide | LEADER NCT01179048 |
9340 T2DM patients with CV risk factors or CVD | 3.8 | 0.87 (0.78-0.97) | 0.78 (0.66-0.93) | 0.87 (0.73-1.05) | 4 |
| Semaglutide | SUSTAIN-6 NCT01720446 |
3297 T2DM patients with CV risk factors or CVD | 2.1 | 0.74 (0.58-0.95) | 0.98 (0.65-1.48) | 1.11 (0.77-1.61) | 22 |
| Exenatide | EXSCEL NCT01144338 |
14752 T2DM patients with CV risk factors or CVD | 3.2 | 0.91 (0.83-1.00) | 0.88 (0.76-1.02) | 0.94 (0.78-1.13) | 26 |
| Albiglutide | Harmony Outcomes NCT02465515 |
9463 T2DM patients with high CV risk. | 1.6 | 0.78 (0.68-0.90) | 0.93(0.73-1.19) | 0.85 (0.70-1.04) | 27 |
| Dulaglutide | REWIND NCT01394952 |
9901 T2DM patients with CV risk factors or CVD | 5.4 | 0.88 (0.79-0.99) | 0.91 (0.78-1.06) | 0.93 (0.77-1.12) | 23 |
| Oral semaglutide | PIONEER 6 Clinical Trials NCT02692716 |
3183 patients,most had cardiovascular or chronic kidney disease | 1.3 | 0.79 (0.57-1.11) | 0.49 (0.27-0.92) | 0.86 (0.48-1.44) | 52 |